A Microneedle Patch That Delivers Liraglutide Through the Skin Without Traditional Injections

Researchers fabricated dissolving microneedle patches with pure liraglutide at the needle tips using a micro-molding technique. They confirmed drug localization using Raman imaging and tested mechanical strength for skin penetration. Pharmacokinetic studies were conducted in Sprague-Dawley rats and Göttingen minipigs, comparing microneedle delivery to subcutaneous injection. Anti-hyperglycemic effects were tested in streptozotocin-induced diabetic rats. Skin tolerability was assessed with 7 days of daily minipig application.

Millions of people use injectable GLP-1 drugs like liraglutide daily, and needle phobia is a real barrier to adherence. A painless patch that delivers the same drug through the skin could dramatically improve patient compliance. This study's innovation — packing pure drug into the needle tips instead of diluting it with fillers — solves the longstanding problem of microneedles not carrying enough medication to be therapeutically useful.

The microneedle patch field has struggled with a fundamental problem: dissolving needles are tiny, and mixing drug with structural excipients severely limits how much medication they can carry. This pure-drug-tip approach represents a potential breakthrough, and testing in minipigs (whose skin closely resembles human skin) makes the results more translatable than rodent-only studies. If this technology reaches humans, it could transform how peptide drugs are administered across multiple therapeutic areas.

This is a preclinical study — no human data yet. The 46.3% bioavailability in minipigs (closer to human skin than rats) means nearly half the drug doesn't reach the bloodstream, which may require larger patches or more frequent application. The study was short-term; long-term skin effects of repeated application are unknown. Manufacturing scalability of pure-drug microneedle tips has not been demonstrated.